Fig. 3From: Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter studyPost-progression survival of patients with acquired resistance, stratified based on presence or absence of oligoprogression. HR, hazard ratio; CI, confidence interval. Generated using JMP software (version 14; SAS Institute, Cary, NC, USA)Back to article page